14-day Premium Trial Subscription Sign Up For FreeGet Free

ACADIA Pharmaceuticals Inc. Stock Forecast NASDAQ:ACAD

Price Target and Analyst Ratings

Most Recent Rating

On August 05, 2021 "Needham & Company LLC" gave "$30.00 - $26.00" rating for ACAD. The price target was changed from $20.05 to 4.8%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-05 $30.00 - $26.00 Target Lowered by Needham & Company LLC $19.25 $20.05→4.8%
2021-08-05 $31.00 - $28.00 Target Lowered by SVB Leerink $19.25 $21.05→2.7%
2021-08-05 $33.00 - $27.00 Target Lowered by Cantor Fitzgerald $19.25 $21.05→2.7%
2021-08-05 $29.00 - $27.00 Target Lowered by Morgan Stanley $19.25 $21.05→2.7%
2021-07-19 Reiterated by SVB Leerink $23.21 $23.21→1.2%
2021-07-10 $23.71 Target Set by Raymond James $23.71 $23.71+0.0%
2021-07-09 Reiterated by Raymond James $23.71 $23.71+0.0%
2021-07-09 Hold Reiterated by Raymond James $23.71
2021-06-10 Hold Initiated by Berenberg Bank $27.30 $29.00
2021-05-18 Hold Target Raised by Canaccord Genuity $21.39 $26.00 → $27.00
2021-05-12 Hold Reiterated by Canaccord Genuity $21.83 $26.00 → $27.00
2021-05-12 Hold Reiterated by Canaccord Genuity $21.83
2021-05-12 Overweight Target Raised by Morgan Stanley $21.83 $28.00 → $29.00
2021-05-12 Hold Target Raised by Canaccord Genuity $21.83 $26.00 → $27.00
2021-05-06 Overweight Target Raised by Morgan Stanley $20.95 $28.00 → $29.00
2021-05-06 Hold Reiterated by Mizuho $20.95
2021-04-13 Buy - Neutral Reiterated by The Goldman Sachs Group $20.60 $73.00 → $25.00
2021-04-13 Buy - Neutral Reiterated by HC Wainwright $20.60 $43.00 → $18.00
2021-04-13 Buy - Neutral Reiterated by Mizuho $20.60 $25.00
2021-04-13 Buy - Hold Reiterated by Canaccord Genuity $20.60 $40.00 → $26.00
2021-04-13 Overweight Target Lowered by Morgan Stanley $20.60 $50.00 → $28.00
2021-04-13 Buy - Hold Reiterated by Jefferies Financial Group $20.60 $40.00 → $21.00
2021-04-07 Buy - Neutral Downgraded by HC Wainwright $21.23 $43.00 → $18.00
2021-04-06 Outperform Target Lowered by SVB Leerink $20.64 $63.00 → $31.00
2021-04-06 Buy - Hold Downgraded by Jefferies Financial Group $20.64 $40.00 → $21.00
2021-04-06 Buy - Hold Downgraded by Canaccord Genuity $20.64
2021-04-06 Buy - Neutral Downgraded by Mizuho $20.64 $37.00 → $25.00
2021-04-06 Overweight Target Raised by Cantor Fitzgerald $20.64 $33.00 → $45.00
2021-04-06 Buy - Hold Downgraded by Canaccord Genuity $20.64 $40.00 → $26.00
2021-04-06 Overweight Target Lowered by Morgan Stanley $20.64 $50.00 → $28.00
2021-04-05 Buy - Neutral Downgraded by The Goldman Sachs Group $21.18
2021-04-05 Buy Target Lowered by Needham & Company LLC $21.18 $44.00 → $30.00
2021-04-05 Outperform - Market Perform Downgraded by Raymond James $21.18
2021-03-16 Buy - Neutral Reiterated by Bank of America $27.34
2021-03-15 Buy - Hold Reiterated by Stifel Nicolaus $29.99 $68.00 → $27.00
2021-03-15 Buy Target Lowered by HC Wainwright $29.99 $60.00 → $43.00
2021-03-15 Overweight Target Lowered by Morgan Stanley $29.99 $65.00 → $50.00
2021-03-15 Strong-Buy - Outperform Reiterated by Raymond James $29.99 $65.00 → $35.00
2021-03-15 Buy Target Lowered by Needham & Company LLC $29.99 $60.00 → $44.00
2021-03-15 Buy - Neutral Reiterated by Citigroup $29.99 $66.00 → $35.00
2021-03-15 Buy - Neutral Reiterated by Guggenheim $29.99
2021-03-15 Buy Target Lowered by Canaccord Genuity $29.99 $61.00 → $40.00
2021-03-15 Buy - Neutral Reiterated by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $29.99 $66.00 → $35.00
2021-03-10 Buy - Neutral Downgraded by Bank of America $26.89
2021-03-09 Buy Target Lowered by Mizuho $25.02 $70.00 → $55.00
2021-03-09 Strong-Buy - Outperform Downgraded by Raymond James $25.02 $65.00 → $35.00
2021-03-09 Buy - Hold Downgraded by Stifel Nicolaus $25.02 $68.00 → $27.00
2021-03-09 Buy Target Lowered by Needham & Company LLC $25.02 $60.00 → $44.00
2021-03-09 Outperform Reiterated by Royal Bank of Canada $25.02 $60.00 → $36.00
2021-03-09 Buy Target Lowered by HC Wainwright $25.02 $60.00 → $43.00
2021-03-09 Buy - Neutral Downgraded by Guggenheim $25.02
2021-03-09 Buy - Neutral Downgraded by Citigroup $25.02 $66.00 → $35.00
2021-03-09 Buy Reiterated by Canaccord Genuity $25.02 $61.00 → $40.00
2021-03-09 Market Perform Target Lowered by Oppenheimer $25.02 $42.00 → $28.00
2021-03-09 Outperform Target Lowered by Cowen $25.02 $66.00 → $57.00
2021-03-09 Overweight Target Lowered by Morgan Stanley $25.02 $65.00 → $50.00
2021-03-09 Outperform Target Lowered by Royal Bank of Canada $25.02 $60.00 → $36.00
2021-03-09 Buy Target Lowered by Canaccord Genuity $25.02 $61.00 → $40.00
2021-03-03 Overweight Target Raised by Morgan Stanley $47.44 $60.00 → $65.00
2021-03-02 Outperform Target Raised by Royal Bank of Canada $46.94 $55.00 → $63.00
2021-02-25 Overweight Reiterated by Morgan Stanley $47.31 $60.00 → $65.00
2021-02-25 Overweight Target Raised by Morgan Stanley $47.31 $60.00 → $65.00
2021-02-24 Buy Reiterated by Mizuho $48.69
2020-12-29 Overweight Reiterated by Cantor Fitzgerald $53.78 $61.00 → $70.00
2020-12-16 Overweight Target Raised by Morgan Stanley $53.08 $58.00 → $60.00
2020-12-15 Buy Initiated by Mizuho $52.57 $69.00
2020-12-15 Buy Initiated by Mizuho $52.57
2020-11-16 Outperform - Strong-Buy Upgraded by Raymond James $54.63 $65.00
2020-11-05 Overweight Target Raised by Morgan Stanley $48.56 $57.00 → $58.00
2020-10-13 Overweight Target Raised by Morgan Stanley $43.26 $55.00 → $57.00
2020-08-24 Outperform Initiated by Raymond James $38.00
2020-08-20 Overweight Initiated by Morgan Stanley $39.27 $55.00
2020-08-06 Buy Reiterated by HC Wainwright $43.63
2020-08-06 Buy Reiterated by Needham & Company LLC $43.63 $60.00
2020-08-06 Buy Target Raised by Canaccord Genuity $43.63 $56.00 → $60.00
2020-08-06 Outperform Target Lowered by SVB Leerink $43.63 $56.00 → $52.00
2020-08-06 Hold Reiterated by Oppenheimer $43.63 $42.00
2020-07-28 Hold Reiterated by Canaccord Genuity $43.15 $29.00
2020-07-21 Target Lowered by Citigroup $44.69 $69.00 → $63.00
2020-07-21 Overweight Target Lowered by Cantor Fitzgerald $44.69 $63.00 → $61.00
2020-07-21 Positive - Market Perform Target Lowered by Oppenheimer $44.69 $53.00 → $42.00
2020-07-21 Outperform Target Lowered by Royal Bank of Canada $44.69 $61.00 → $55.00
2020-07-21 Buy Reiterated by Jefferies Financial Group $44.69 $60.00
2020-07-16 Buy Initiated by Needham & Company LLC $54.58 $60.00
2020-07-09 Positive - Outperform Target Raised by Royal Bank of Canada $56.07 $58.00 → $61.00
2020-07-06 Hold - Buy Upgraded by Stifel Nicolaus $53.69 $41.00 → $71.00
2020-05-27 Market Perform Target Raised by Oppenheimer $50.63 $48.00 → $53.00
2020-05-08 Buy Reiterated by Needham & Company LLC $50.72
2020-05-08 Buy Reiterated by Cantor Fitzgerald $50.72 $58.00 → $63.00
2020-05-08 Overweight Target Raised by JPMorgan Chase & Co. $50.72 $50.00 → $55.00
2020-05-08 Hold Reiterated by Oppenheimer $50.72 $48.00
2020-04-16 Buy Initiated by Jefferies Financial Group $46.55 $60.00

ACAD Stock Trend

The stock lies the upper part of a wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $16.81 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -39.94% during the next 3 months and, with a 90% probability hold a price between $8.64 and $10.10 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $14.20 $15.42 $16.63
2021-09-21 $14.03 $15.24 $16.45
2021-09-22 $13.85 $15.06 $16.28
2021-09-23 $13.67 $14.89 $16.10
2021-09-24 $13.49 $14.71 $15.92
2021-09-27 $13.32 $14.53 $15.74
2021-09-28 $13.14 $14.35 $15.57
2021-09-29 $12.96 $14.18 $15.39
2021-09-30 $12.78 $14.00 $15.21
2021-10-01 $12.61 $13.82 $15.03
2021-10-04 $12.43 $13.64 $14.86
2021-10-05 $12.25 $13.47 $14.68
2021-10-06 $12.07 $13.29 $14.50
2021-10-07 $11.90 $13.11 $14.32
2021-10-08 $11.72 $12.93 $14.15
2021-10-11 $11.54 $12.76 $13.97
2021-10-12 $11.36 $12.58 $13.79
2021-10-13 $11.19 $12.40 $13.62
2021-10-14 $11.01 $12.22 $13.44
2021-10-15 $10.83 $12.05 $13.26
2021-10-18 $10.66 $11.87 $13.08
2021-10-19 $10.48 $11.69 $12.91
2021-10-20 $10.30 $11.51 $12.73
2021-10-21 $10.12 $11.34 $12.55
2021-10-22 $9.95 $11.16 $12.37
2021-10-25 $9.77 $10.98 $12.20
2021-10-26 $9.59 $10.80 $12.02
2021-10-27 $9.41 $10.63 $11.84
2021-10-28 $9.24 $10.45 $11.66
2021-10-29 $9.06 $10.27 $11.49

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzh... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT